Hostname: page-component-76fb5796d-r6qrq Total loading time: 0 Render date: 2024-04-26T11:16:48.880Z Has data issue: false hasContentIssue false
  • English
  • Français

Prophylactic pacemaker placement at first signs of conduction disease in Kearns–Sayre syndrome

Published online by Cambridge University Press:  17 October 2018

Mira Trivedi ,
Amy Goldstein  and
Gaurav Arora
Mira Trivedi*
Affiliation:
Department of Cardiology, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA
Amy Goldstein
Affiliation:
Department of Neurology, Children’s Hospital of Philadelphia, Philadelphia, PA, USA
Gaurav Arora
Affiliation:
Department of Cardiology, Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA, USA
*
Author for correspondence: M. Trivedi, MD, Department of Pediatrics, Children’s Hospital of Pittsburgh of UPMC, 4401 Penn Ave, Pittsburgh, PA 15224, USA. Tel: 937 367 5996; Fax: 412 692 5138; E-mail: mira.trivedi@chp.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

Cardiac conduction disease affects patients with Kearns–Sayre syndrome. We report a young asymptomatic patient with Kearns–Sayre syndrome with abnormal conduction on electrocardiogram and Holter monitor, although not advanced atrioventricular block. She underwent prophylactic pacemaker placement, and rapidly developed complete atrioventricular block, which resulted in 100% ventricular pacing. It may be reasonable to consider prophylactic pacemaker implantation in patients with Kearns–Sayre syndrome with evidence of cardiac conduction disease even without overt atrioventricular block given its unpredictable progression to complete atrioventricular block.

Keywords

Kearns–Sayre syndromepacemakerconductionpediatrics
Type
Brief Report
Information
Cardiology in the Young , Volume 28 , Issue 12 , December 2018 , pp. 1487 - 1488
Copyright
© Cambridge University Press 2018 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Gorman, GS , Schaefer, AM , Ng, Y , et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol 2015; 77: 753–759.Google Scholar
2. U.S. National Library of Medicine. Kearns-Sayre Syndrome – Genetics Home Reference – NIH, 2018. Retrieved December 2011, ghr.nlm.nih.gov/condition/kearns-sayre-syndrome Google Scholar
3. van Beynum, I , Morava, E , Taher, M , et al. Cardiac arrest in Kearns–Sayre syndrome. JIMD Rep 2012; 2: 7–10.Google Scholar
4. Young, TJ , Shah, AK , Lee, MH , Hayes, DL . Kearns-Sayre syndrome: a case report and review of cardiovascular complications. Pacing Clin Electrophysiol 2005; 28: 454–457.Google Scholar
5. DiMauro, S , Hirano, M . Mitochondrial DNA deletion syndromes. In: Gene Reviews, 1993: 1-11. https://doi.org/NBK1203[bookaccession].Google Scholar
6. Kabunga, P , Lau, AK , Phan, K , et al. Systematic review of cardiac electrical disease in Kearns-Sayre syndrome and mitochondrial cytopathy. Int J Cardiol 2015; 181: 303–310.Google Scholar
7. Epstein, AE , DiMarco, JP , Ellenbogen, KA . ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation 2008; 117: e350–e408.Google Scholar
8. Polak, P , Zulstra, F , Roelandt, J . Indications for pacemaker implantation in the Kearns-Sayre syndrome. Eur Heart J 1989; 10: 281–282.Google Scholar